FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 444 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR COVID-19, Vaccines, and the Immune System: Emerging Research from NCI’s SeroNet August 30, 2021 Coronavirus and COVID-19: What People With Cancer Need to Know June 21, 2020 Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and... December 7, 2022 FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... April 15, 2022 Load more HOT NEWS We want every scientist to thrive in cancer research What Happens If More People Get Screened for Cancer? Middle Schooler Starts Business to Help Provide Spa and Salon Services... Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs...
